JP2022541761A5 - - Google Patents
Info
- Publication number
- JP2022541761A5 JP2022541761A5 JP2022502074A JP2022502074A JP2022541761A5 JP 2022541761 A5 JP2022541761 A5 JP 2022541761A5 JP 2022502074 A JP2022502074 A JP 2022502074A JP 2022502074 A JP2022502074 A JP 2022502074A JP 2022541761 A5 JP2022541761 A5 JP 2022541761A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- target protein
- constituent polypeptide
- fused
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874025P | 2019-07-15 | 2019-07-15 | |
| US62/874,025 | 2019-07-15 | ||
| PCT/IB2020/056657 WO2021009692A1 (en) | 2019-07-15 | 2020-07-15 | Tripartite systems for protein dimerization and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022541761A JP2022541761A (ja) | 2022-09-27 |
| JP2022541761A5 true JP2022541761A5 (cg-RX-API-DMAC7.html) | 2023-07-18 |
| JP7772687B2 JP7772687B2 (ja) | 2025-11-18 |
Family
ID=71895034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502074A Active JP7772687B2 (ja) | 2019-07-15 | 2020-07-15 | タンパク質二量体化の三分子システム及び使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220380801A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3999091A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7772687B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114127304B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021009692A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240044467A (ko) * | 2021-08-09 | 2024-04-04 | 하버 바이오메드 (상하이) 컴퍼니 리미티드 | Cldn18.2-표적화 항체, 이중특이적 항체, 및 이들의 용도 |
| KR20250087608A (ko) * | 2022-10-10 | 2025-06-16 | 메디뮨 엘엘씨 | 클라우딘 18.2를 표적화하는 키메라 항원 수용체로 암을 치료하는 조성물 및 방법 |
| JP2026525824A (ja) | 2023-06-23 | 2026-08-04 | アストラゼネカ・アクチエボラーグ | 分子スイッチ |
| CN116925190B (zh) * | 2023-07-27 | 2026-03-24 | 浙江大学 | 一种靶向抑制DEF-p65复合物的多肽、多肽药物及其应用 |
| CN117299070B (zh) * | 2023-10-11 | 2025-09-12 | 安徽工业大学 | 一种Ca/Mg矿物凝胶的制备方法及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US20040040047A1 (en) | 1998-03-30 | 2004-02-26 | Spencer David M. | Regulated apoptosis using chemically induced dimerization of apoptosis factors |
| IL143798A0 (en) | 1999-01-08 | 2002-04-21 | Bristol Myers Squibb Co | Hepatitis c virus ns3 protease |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| DK3246403T3 (da) | 2005-10-18 | 2020-10-26 | Prec Biosciences | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
| EP2215246B1 (en) | 2007-10-31 | 2015-01-07 | MedImmune, LLC | Protein scaffolds |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| KR20130056870A (ko) | 2010-04-13 | 2013-05-30 | 메디뮨 엘엘씨 | 피브로넥틴 ⅲ형 도메인에 기초한 다량체 스캐폴드 |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| WO2015110048A1 (en) * | 2014-01-23 | 2015-07-30 | Sunshine Lake Pharma Co., Ltd. | Bridged ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
| US10954500B2 (en) | 2015-10-23 | 2021-03-23 | Fred Hutchinson Cancer Research Center | Methods to create chemically-induced dimerizing protein systems for regulation of cellular events |
| CN108239656A (zh) * | 2016-12-27 | 2018-07-03 | 天津天锐生物科技有限公司 | 一种小分子药物控制的蛋白功能开关系统 |
| AU2018270515A1 (en) * | 2017-05-19 | 2019-12-05 | The Regents Of The University Of California | Antibody chemically induced dimerizer (abCID) as molecular switches for regulating cellular therapies |
| CN108329332A (zh) * | 2018-03-16 | 2018-07-27 | 安徽华昌高科药业有限公司 | 一种制备Glecaprevir的方法 |
-
2020
- 2020-07-15 US US17/627,210 patent/US20220380801A1/en active Pending
- 2020-07-15 CN CN202080050513.7A patent/CN114127304B/zh active Active
- 2020-07-15 JP JP2022502074A patent/JP7772687B2/ja active Active
- 2020-07-15 WO PCT/IB2020/056657 patent/WO2021009692A1/en not_active Ceased
- 2020-07-15 EP EP20749942.7A patent/EP3999091A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102944460B1 (ko) | Cldn18.2 및 cd3에 대한 항체 작제물 | |
| CN109476734B (zh) | Cd70和cd3的抗体构建体 | |
| CN107922495B (zh) | 结合egfrviii和cd3的双特异性抗体构建体 | |
| JP7011574B2 (ja) | Flt3及びcd3に対する抗体構築物 | |
| CA2454361C (en) | Humanized antibodies | |
| BR112021006558A2 (pt) | proteínas de ligação triespecíficas anti-cd38, anti-cd28 e anti-cd3 e métodos de uso para o tratamento de infecção viral | |
| CN119371549A (zh) | 结合dll3和cd3的双特异性抗体构建体 | |
| JP2022513383A (ja) | 二重特異性抗体及びその作製方法と使用 | |
| BR112020011627A2 (pt) | processo de fabricação contínuo para produtos de anticorpos biespecíficos | |
| CN116964102A (zh) | 四价fzd和wnt共受体结合抗体分子及其用途 | |
| JP2023178502A (ja) | 抗cd38及び抗cd138キメラ抗原受容体を含むt細胞、及びその用途 | |
| CN115160433B (zh) | 人源化hbv b和c基因型前s1蛋白抗体及其应用 | |
| CN117164712B (zh) | 一种靶向cd22的单域抗体、嵌合抗原受体及其应用 | |
| CN110494163A (zh) | 凝血因子viii模拟蛋白及其用途 | |
| WO2023125813A1 (zh) | 抗间皮素纳米抗体嵌合抗原受体及其应用 | |
| CN112789058A (zh) | 双特异性抗体构建体的下游加工 | |
| CN110885377A (zh) | 抗cd47/vegf双特异性抗体及其应用 | |
| CN117279947A (zh) | 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子 | |
| TWI910636B (zh) | 特異性結合cll1的抗體及其製法和應用 | |
| CN107880131A (zh) | 一种抗IL‑13Rα2和CD3双特异抗体及其应用 | |
| CN116496400A (zh) | 抗c-Met和抗MSLN抗体、其双嵌合抗原受体及其应用 | |
| WO2024193669A1 (zh) | 抗tnfr2/抗pd-1或ctla-4双特异性抗体及其应用 | |
| TWI904917B (zh) | Taci結合分子 | |
| WO2026016967A1 (zh) | 一种融合蛋白及其用途 | |
| CN117915950A (zh) | 一种多特异性抗体及其用途 |